Earnings Feed
Start Free
Home/Filings/4/0001628280-26-002199
4//SEC Filing

Stone Warren 4

Accession 0001628280-26-002199

CIK 0001077183other
View on SEC.govCompany Profile

Filed

Jan 14, 7:00 PM ET

Accepted

Jan 15, 4:22 PM ET

Size

30.3 KB

Accession

0001628280-26-002199

Insider Transaction Report

Form 4
Period: 2026-01-13
NEOGENOMICS INCNEO
Stone Warren
Pres & Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-13+59,382→ 158,886 total
  • Tax Payment

    Common Stock

    [F2]
    2026-01-13−15,127→ 143,759 total
Holdings

  • Stock Option (Right to Buy)

    [F3]
    Exercise: $11.21Exp: 2029-12-01→ Common Stock (166,113 underlying)
    166,113

  • Stock Option (Right to Buy)

    [F4]
    Exercise: $19.65Exp: 2030-05-11→ Common Stock (53,969 underlying)
    53,969

  • Performance Stock Unit

    [F5][F6]
    Exercise: $0.00From: 2026-05-11→ Common Stock (21,204 underlying)
    21,204

  • Restricted Stock Unit

    [F7][F6]
    Exercise: $0.00→ Common Stock (9,613 underlying)
    9,613

  • Stock Option (Right to Buy)

    [F8]
    Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
    42,344

  • Restricted Stock Unit

    [F9][F6]
    Exercise: $0.00→ Common Stock (16,886 underlying)
    16,886

  • Performance Stock Unit

    [F10][F6]
    Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
    25,330

  • Stock Option (Right to Buy)

    [F11]
    Exercise: $13.96Exp: 2034-05-02→ Common Stock (29,976 underlying)
    29,976

  • Restricted Stock Unit

    [F12][F6]
    Exercise: $0.00→ Common Stock (17,908 underlying)
    17,908

  • Performance Stock Unit

    [F13][F6]
    Exercise: $0.00From: 2027-05-02→ Common Stock (17,908 underlying)
    17,908

  • Restricted Stock Unit

    [F6]
    Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
    59,382

  • Stock Option (Right to Buy)

    [F14][F15]
    Exercise: $13.05Exp: 2035-02-21→ Common Stock (143,266 underlying)
    143,266

  • Restricted Stock Unit

    [F16][F6]
    Exercise: $0.00→ Common Stock (84,317 underlying)
    84,317

  • Stock Option (Right to Buy)

    [F17][F18]
    Exercise: $10.44Exp: 2035-04-01→ Common Stock (94,518 underlying)
    94,518

  • Restricted Stock Unit

    [F19][F6]
    Exercise: $0.00→ Common Stock (52,687 underlying)
    52,687
Footnotes (19)
  • [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
  • [F10]On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
  • [F11]On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F12]On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F13]On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
  • [F14]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%
  • [F15]On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President &Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
  • [F16]On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate.
  • [F17]This stock option was granted as a premnium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
  • [F18]On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
  • [F19]On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
  • [F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
  • [F3]On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F4]On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F5]On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
  • [F6]Once vested, the shares of common stock are not subject to expiration.
  • [F7]On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F8]On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F9]On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-01-15

Documents

1 file

Issuer

NEOGENOMICS INC

CIK 0001077183

→
Entity typeother

Related Parties

1
  • filerCIK 0001955295

Filing Metadata

Form type
4
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 4:22 PM ET
Size
30.3 KB
View on SEC.gov